Capricor Therapeutics, Inc.
Capricor Therapeutics is a clinical-stage biotechnology company developing allogeneic cardiosphere-derived cell therapies (Deramiocel) for Duchenne muscular dystrophy and a proprietary exosome platform (StealthX) for vaccines and therapeutic delivery.
- Company typePublic
- Founded2013
- HeadquartersSan Diego, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Capricor Therapeutics, Inc. does
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapeutics for rare and serious diseases. The company's lead product candidate is Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell (CDC) therapy that targets Duchenne muscular dystrophy (DMD) and DMD-associated cardiomyopathy. Capricor's HOPE-2 and HOPE-3 trials have reported statistically significant preservation of cardiac function and met primary efficacy endpoints on upper limb performance, and the company has resubmitted a Biologics License Application with an FDA PDUFA target action date of August 22, 2026. Capricor has also developed the proprietary StealthX exosome platform, which enables adjuvant-free vaccine and therapeutic delivery of nucleic acids and proteins, with active programs in SARS-CoV-2 vaccination (under NIH Project NextGen) and preclinical rare-disease applications such as arginase-1 deficiency.
Capricor Therapeutics, Inc. firmographics
Firmographics- Name
- Capricor Therapeutics, Inc.
- Legal name
- Capricor Therapeutics, Inc.
- Website
- https://capricor.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Short description
- Capricor Therapeutics is a clinical-stage biotechnology company developing allogeneic cardiosphere-derived cell therapies (Deramiocel) for Duchenne muscular dystrophy and a proprietary exosome platform (StealthX) for vaccines and therapeutic delivery.
- Ownership category
- akta.pro rank
Capricor Therapeutics, Inc. industry classification
Industry- Product category
- Biopharmaceuticals
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Capricor Therapeutics, Inc. is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Capricor Therapeutics, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales
Revenue model
- Product Revenue (Future): Capricor is pre-revenue with no commercialized products. The company anticipates potential revenue from Deramiocel (CAP-1002) sales pending FDA approval, with partnership arrangements with Nippon Shinyaku for US and Japan commercialization.
- Partnership Milestone Payments: The company receives or anticipates milestone payments from commercial partners including Nippon Shinyaku/NS Pharma contingent on regulatory and commercial milestones.
- Government Grants: Non-dilutive funding from NIH/Project NextGen supporting exosome vaccine development. The company has received grant funding for Phase 1 clinical studies with the StealthX vaccine.
- Public Offerings: Capital raised through underwritten public offerings of common stock, including $150 million offering in December 2025 and $23 million offering in September 2023.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Capricor Therapeutics, Inc. product offering
Product offeringCore offering
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy targeting Duchenne muscular dystrophy and associated cardiomyopathy. The company also operates the proprietary StealthX exosome platform for vaccine and therapeutic development.
Product overview
Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics. The core product is Deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy currently under FDA review. Supporting this is the StealthX™ exosome platform technology, which enables delivery of nucleic acids and proteins for vaccine and therapeutic applications. The company operates with a multi-stage pipeline exploring allogeneic cardiosphere-derived cells and exosome science, with additional programs including a SARS-CoV-2 vaccine candidate under NIH Project NextGen collaboration and preclinical exosome programs for rare diseases.
Differentiator
Problem solved
Functional benefit
Brands
- StealthX™: Proprietary exosome platform technology for vaccine and therapeutic development, including multivalent vaccine candidates for SARS-CoV-2 and exosome-based delivery of mRNA and other payloads.
- Deramiocel
Products and services
- Deramiocel (CAP-1002) An allogeneic cardiosphere-derived cell (CDC) therapy for treating Duchenne muscular dystrophy and associated cardiomyopathy. Currently in late-stage clinical development with Biologics License Application under FDA review (PDUFA target action date August 22, 2026).
- StealthX Exosome Platform Proprietary exosome-based technology platform for developing vaccines and therapeutics. Engineered exosomes capable of delivering nucleic acids, proteins, and other payloads to treat or prevent various diseases.
- StealthX SARS-CoV-2 Vaccine Multivalent exosome-based vaccine candidate targeting SARS-CoV-2, delivering both spike (S) and nucleocapsid (N) proteins. Part of NIH Project NextGen initiative with NIAID-conducted Phase 1 clinical study. The platform is free of adjuvant and lipid nanoparticles.
- StealthX ARG1-D Program Exosome-based therapeutic approach for arginase-1 deficiency (ARG1-D), a rare genetic metabolic disease, utilizing engineered exosomes expressing human Arg1 enzyme.
Quantifiable outcome
- 91% slowing of cardiac disease progression (preservation of left ventricular ejection fraction)
- +1 more outcomes
Companies that use Capricor Therapeutics, Inc.
Customer profileSegments1 record
Ideal customer profiles2 records
Capricor Therapeutics, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Capricor Therapeutics, Inc. partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- National Institutes of Health (NIH) / Project NextGenflagshipCapricor's StealthX exosome-based multivalent vaccine for SARS-CoV-2 was selected for Project NextGen, an initiative by the U.S. Department of Health and Human Services. NIAID will conduct Phase 1 clinical study with Capricor's vaccine candidate. This collaboration provides non-dilutive funding for clinical advancement.
- Johns Hopkins UniversitycoreExclusive worldwide licensing agreement with Johns Hopkins University for engineered exosome technology for vaccines and therapeutics. The licensed technology is based on preclinical research conducted by Dr. Stephen Gould, who serves as Capricor's executive consultant. Capricor and JHU have collaborated over a decade on technologies in chronic heart failure, cardiovascular, genetic and muscular diseases.
- LonzacoreManufacturing collaboration with Lonza for the development of CAP-1002 for Duchenne muscular dystrophy and other indications. The partnership supports commercial-scale manufacturing capabilities.
- Cedars-Sinai Medical CentercoreLong-standing research collaboration with Cedars-Sinai Heart Institute. Clinical trials including ALLSTAR Phase I trial were conducted at Cedars-Sinai. Dr. Raj R. Makker presented Phase I results. Capricor was formed from merger with Nile Therapeutics in 2013, with roots in Cedars-Sinai research.
- Nippon Shinyaku Co., Ltd. / NS Pharma, Inc.coreCapricor entered into a partnership with Nippon Shinyaku for exclusive commercialization and distribution of CAP-1002 for Duchenne muscular dystrophy in the United States and Japan. The partnership is subject to regulatory approval. Capricor has also filed a rescission action against Nippon Shinyaku and NS Pharma regarding the distribution agreement.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Capricor Therapeutics, Inc. competitors and assessment
Company assessmentDirect peers
- Mesoblast: Mesoblast develops allogeneic cell therapies for inflammatory and cardiovascular diseases, including those derived from proprietary cell sources. Capricor's CAP-1002 (allogeneic cardiosphere-derived cells) shares allogeneic cell-therapy manufacturing, regulatory, and commercial dynamics with Mesoblast's portfolio.
- PTC Therapeutics: PTC Therapeutics markets DMD therapies including Translarna (ataluren) and is developing additional DMD programs. Capricor and PTC both target the same neuromuscular specialists and DMD patient community with disease-modifying biologics.
- Sarepta Therapeutics: Sarepta is the leading commercial-stage biotech focused exclusively on Duchenne muscular dystrophy. Both companies develop biologic therapies targeting DMD and compete for the same patient population and physician-prescriber base, making Sarepta Capricor's most direct competitive comparator.
- Solid Biosciences: Solid Biosciences develops gene and cell-based therapies for Duchenne muscular dystrophy. Both Capricor and Solid are clinical-stage DMD-focused biotechs developing next-generation biologics (cell therapy and gene therapy respectively) for the same monogenic disease.
Emerging players
- CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene-editing biotech with overlapping modality (nucleic-acid delivery, ex vivo cell therapy). Capricor's exosome-mediated nucleic acid and protein delivery has conceptual overlap with CRISPR's therapeutic delivery challenges in monogenic disease.
- Evox Therapeutics: Evox Therapeutics is a clinical-stage biotech focused on engineering extracellular vesicles/exosomes for nucleic acid and protein delivery to treat rare diseases. Evox is the closest direct peer to Capricor's StealthX exosome platform, sharing the engineered-exosome therapeutic modality.
Broad incumbents
- BioMarin Pharmaceutical: BioMarin is an established rare-disease biotech with multiple approved biologics. Both companies operate in rare disease biologics with complex manufacturing and global distribution, providing a useful broader-incumbent benchmark for Capricor's commercialization path.
- Vertex Pharmaceuticals: Vertex is a major biotech with established cell and gene therapy capabilities (notably in sickle cell disease and CASGEVY). Capricor's allogeneic CDC therapy and exosome-mediated nucleic acid delivery share cell-therapy manufacturing and regulatory dynamics with Vertex's modality.
- Ultragenyx Pharmaceutical: Ultragenyx is a clinical and commercial rare-disease biotech advancing biologics and gene therapies. Capricor's StealthX enzyme-replacement programs (e.g., ARG1-D) and DMD cell therapy are directly comparable to Ultragenyx's rare-disease biologic pipeline.
- bluebird bio: bluebird bio develops gene and cell therapies for rare genetic diseases, requiring similar FDA regulatory pathways and complex biological manufacturing as Capricor's Deramiocel. Both companies target small rare-disease patient populations with high-cost biologic modalities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Capricor Therapeutics, Inc. social profiles
Digital presenceCapricor Therapeutics, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Capricor Therapeutics, Inc. leadership team
Management profileNumber of profiles
Profiles9 records
Capricor Therapeutics, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Capricor Therapeutics, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Capricor Therapeutics, Inc.
What does Capricor Therapeutics, Inc. do?
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapeutics. Its lead product candidate, Deramiocel (CAP-1002), is an allogeneic cardiosphere-derived cell therapy targeting Duchenne muscular dystrophy and associated cardiomyopathy. The company also operates the proprietary StealthX exosome platform for vaccine and therapeutic development.
Is Capricor Therapeutics, Inc. a public or private company?
Capricor Therapeutics, Inc. is a public company. It is classified as public and is currently operating.
When was Capricor Therapeutics, Inc. founded?
Capricor Therapeutics, Inc. was founded in 2013.
Where is Capricor Therapeutics, Inc. based?
Capricor Therapeutics, Inc. is headquartered in San Diego, United States, in the North America region.
How does Capricor Therapeutics, Inc. make money?
Four revenue lines are on record. Product Revenue (Future) is the primary driver. The others are partnership Milestone Payments, government Grants and public Offerings.
Who are Capricor Therapeutics, Inc.'s main competitors?
Direct peers on record are Mesoblast, PTC Therapeutics, Sarepta Therapeutics and Solid Biosciences. Emerging players are CRISPR Therapeutics and Evox Therapeutics. Broad incumbents are BioMarin Pharmaceutical, Vertex Pharmaceuticals, Ultragenyx Pharmaceutical and bluebird bio.
Does Capricor Therapeutics, Inc. have an API?
No public API is recorded for Capricor Therapeutics, Inc..
What industry is Capricor Therapeutics, Inc. in?
Capricor Therapeutics, Inc.'s product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its SIC code is 2836.